NCT02868892终止2 期
A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
详细描述
Patients will receive Pemetrexed 500 mg/m2 every three week.
On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have had advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix with documented disease progression
- •Patients must have had measurable disease defined as at least one lesion that could be accurately measured in at least one dimension, which must have been 20 mm when measured by conventional techniques including palpation, plain X-ray, computerized tomography (CT), and magnetic resonance imaging(MRI) or 10 mm when measured by spiral CT
- •18 years of age or older
- •Eastern Cooperative Oncology Group (ECOG) performance status score < 2 and a life expectancy >3 months
- •Life expectancy ≥ 12 weeks
- •Participants must have measureable disease by RECIST criteria
- •Absolute neutrophil count > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL
- •Creatinine clearance ≥ 45 mL/min using the standard Cockcroft and Gault formula (below) or glomerular filtration rate (GFR) measured by Tc99m-diethylenetriaminepentacetate (DPTA) serum clearance method:
- •Males: [140 - Age in years] × Actual Body Weight (kg) 72 × Serum Creatinine (mg/dL)
- •Females: Estimated creatinine clearance for males × 0.85
- •Total bilirubin ≤ 2 mg/dL, aspartate transaminase (AST) and alanine transaminase (ALT) AST/ALT ≤ 5 times the upper limit of normal range
- •At least 21 days from administration of chemotherapy
- •No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to be clinically insignificant by the Principal Investigator
- •At least four (4) weeks from prior major surgery
- •Willingness to provide permission to access archived tumor samples and additional blood samples for evaluation of Foundation One Analysis where available Enterprise wide.
- •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
排除标准
- •Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or hypertension.
- •Myocardial infarction or unstable angina within 2 months of treatment.
- •Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
- •Active clinically serious infection > CTCAE (version 4.03) Grade
- •Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- •Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of study drug.
- •Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study drug.
- •Serious non-healing wound, ulcer, or bone fracture.
- •Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
- •Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
- •Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.
研究组 & 干预措施
Pemetrexed
Experimental
Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
干预措施: Pemetrexed (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: 2 years
Evaluate the progression free survival of recurrent cervical adenocarcinoma. Progression-Free Survival is defined as the period of time from the date of first study drug administration to the date that the subject is determined to have progressive disease or death due to any cause.
次要结局
- Response Rate(2 years)
- Overall Survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine CancerEndometrial CancerUterine CancerCervical CancerNCT03192059University Hospital, Ghent43
终止
2 期
Study of Pemetrexed for Second-Line Pancreas CancerPancreas CancerNCT00864513Georgetown University17
已完成
2 期
A Trial for Patients With Advanced/Recurrent Endometrial CancerNeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, FemaleUterine NeoplasmsEndometrial NeoplasmsCancer of EndometriumEndometrial CancerCancer of the EndometriumEndometrium CancerNeoplasms, EndometrialNCT00377520Eli Lilly and Company27
已完成
2 期
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck CancerHead and Neck NeoplasmsNCT01057589Eli Lilly and Company66
Unknown
2 期
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical CancerCervical CancerNCT04974827Hunan Cancer Hospital46